Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07659678 · ClinicalTrials.gov registry record · Phase 2
CCR2 PET Imaging Head and Neck Squamous Cell Carcinoma
A Phase 2 study, sponsored by Washington University School of Medicine.
- Not yet
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT07659678: Clinical Trial Phase 2 study, sponsored by Washington University School of Medicine.
NCT07659678 is a Phase 2 study that has not yet begun recruiting, run by Washington University School of Medicine. The registered enrollment target is 90 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07659678, a Phase 2 study, has not yet begun recruiting, sponsored by Washington University School of Medicine.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
This is a prospective study to evaluate the sensitivity and specificity of Cu-64 DOTA-ECL1i PET/CT imaging to serve as a novel precision imaging tool for patients with head and neck squamous cell carcinoma (HNSCC).
Primary Outcome
64Cu-DOTA-ECL1i PET uptake will be assessed using standardized update value maximum (SUVmax). SUV is a decay-corrected measurement of activity per volume of tissue (µCi/mL) divided by the average activity per unit mass in the entire body and/or tumor-to-normal-tissue-ratio. SUVmax is the highest measured uptake of a tracer of a lesion on a PET scan.
Interventions
- DRUG 64Cu-DOTA-ECL1i
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2026-08-31 |
| Est. Completion | 2032-03-31 |
| Phase | Phase 2 |
What is known before NCT07659678 opens enrollment
NCT07659678 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% lower).
The record links to 0 conditions, and to 1 intervention - of which 64Cu-DOTA-ECL1i is the first listed.
NCT07659678 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07659678 about?
NCT07659678 is a clinical study titled "CCR2 PET Imaging Head and Neck Squamous Cell Carcinoma". This is a prospective study to evaluate the sensitivity and specificity of Cu-64 DOTA-ECL1i PET/CT imaging to serve as a novel precision imaging tool for patients with head and neck squamous cell carcinoma (HNSCC).
What is the current status of trial NCT07659678?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2026-08-31. Estimated completion is 2032-03-31.
What interventions are being tested in trial NCT07659678?
The interventions under investigation include: 64Cu-DOTA-ECL1i (DRUG).
Who is sponsoring clinical trial NCT07659678?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07659678's enrollment target sits among peer trials
90 772nd of 2000 higher than 1,199 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI